Hit And Miss First Half For Takeda
Executive Summary
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
You may also be interested in...
Takeda Looks To Ride 'Wave 1' To JPY5tn Target
Takeda tries to get investors as excited as it is about the first wave of post-R&D reorganization candidates coming through, as it lays out 'ambitious but achievable' revenue target.
Takeda Confirms $2.3bn Deal With Blackstone For Japan Consumer Business
In a widely anticipated move, Takeda has confirmed the sale of its consumer healthcare business in Japan, to the US private equity group Blackstone.
Strong Early Promise For Takeda 'Off The Shelf' CAR-NK Therapy
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.